Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Placebo-controlled Study to Determine the Safety, Tolerability, Pharmacodynamics and Clinical Efficacy of ILV-094 (an IL-22 Antibody) Administered Intravenously to Subjects With Atopic Dermatitis (AD)

NCT01941537 is registered in ClinicalTrials.gov with Rockefeller University as lead sponsor.

NCT NCT01941537
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01941537 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Placebo-controlled Study to Determine the Safety, Tolerability, Pharmacodynamics and Clinical Efficacy of ILV-094 (an IL-22 Antibody) Administered Intravenously to Subjects With Atopic Dermatitis (AD)
Lead sponsor
Rockefeller University
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2013
Completion date
January 31, 2019
Enrollment
60 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis